 Connection
Jeannette Lee to Prognosis
This is a "connection" page, showing publications Jeannette Lee has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.091 |
|
|
|
-
Tummel E, Ochoa D, Korourian S, Betzold R, Adkins L, McCarthy M, Hung S, Kalkwarf K, Gallagher K, Lee JY, Klimberg VS. Does Axillary Reverse Mapping Prevent Lymphedema After Lymphadenectomy? Ann Surg. 2017 05; 265(5):987-992.
Score: 0.025
-
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov; 99(11):1731-7.
Score: 0.021
-
Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 01; 31(1):58-64.
Score: 0.019
-
Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009 Oct 20; 27(30):5039-48.
Score: 0.015
-
Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 01; 106(5):1538-43.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|